Oramed Pharmaceuticals (ORMP) Cash from Operations (2010 - 2026)

Oramed Pharmaceuticals has reported Cash from Operations for 17 years, with the latest figure at 2915000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 17.16% year-over-year to 2915000.0; the trailing twelve-month figure through Mar 2026 stood at 8541000.0 (up 18.31% YoY), and the FY2025 full-year result was 9145000.0, down 8.71% from the prior year.
• Cash from Operations for Q1 2026 stood at 2915000.0, down from 466000.0 in the prior quarter.
• The five-year high for Cash from Operations was 2076000.0 in Q2 2024, with the low at 9125000.0 in Q1 2022.
• Historically, Cash from Operations has averaged 3452058.82 across 5 years, with a median of 2634000.0 in 2023.
• The largest YoY upside for Cash from Operations was 178.82% in 2024 against a maximum downside of 923.2% in 2024.
• Oramed Pharmaceuticals' Cash from Operations stood at 8062000.0 in 2022, then soared by 82.41% to 1418000.0 in 2023, then tumbled by 34.77% to 1911000.0 in 2024, then surged by 75.61% to 466000.0 in 2025, then slumped by 525.54% to 2915000.0 in 2026.
• The last three Cash from Operations figures came in at 2915000.0 (Q1 2026), 466000.0 (Q4 2025), and 1625000.0 (Q3 2025), per Business Quant data.